Exit this survey BioNJ CEO Survey Question Title * 1. The CEOs of pharmaceutical and biotech companies must address numerous—and sometimes conflicting—factors when guiding their companies. Which strategic issues or operational concerns are most important to you as you navigate today’s challenging economic environment? (Choose all that apply.) Alternative partnering and financing approaches Deciding to go commercial versus partnering/out-licensing Commercialization strategies for early-stage assets Dealmaking outlook: does Big Pharma want what you have? Doing more with less – maximizing increasingly limited financing options Other (please specify) Question Title * 2. Healthcare reform has introduced yet another complexity into the current healthcare landscape. While some of the provisions of the Patient Protection and Affordable Care Act promise to increase the number of potential health care consumers, other provisions, meant to control costs, are expect to decrease biopharma profits because of formulary pressure.Has your company considered any of the following strategies to meet the challenges of helathcare reform? Examining how comparative effectiveness drug trials impact reimbursement possibilities Steering investment toward drug classes that are less vulnerable to formulary pressure Including biosimilars planning in your strategic outlook Other (please specify) Question Title * 3. Are you aware of the BioNJ Preferred Vendor cost-saving benefits available for BioNJ Members? Yes No Question Title * 4. Would you like more information about money-saving business solutions for your company? No. Yes - please send me information at the following email address: Done
